# Renal Medication Safety: Dose, Reconcile, Reassess

Renal prescribing is a repeated process: choose the correct clearance estimate, recognize accumulation, and update the plan when physiology changes.

![Infographic: Renal Medication Safety: Dose, Reconcile, Reassess](https://urinenephrology.org/visual-reference/images/renal-medication-safety.png?v=20261003c)

## Match the estimate to the drug

Check whether the label uses creatinine clearance, indexed eGFR, or another method. At body-size extremes, indexed mL/min/1.73 m² differs from absolute mL/min. When a small error changes a high-risk dose, use a more accurate assessment and pharmacist review.

## Changing creatinine means changing exposure

Steady-state eGFR can mislead during AKI and recovery. Review the next maintenance dose using the trend, urine output, drug levels when available, and dialysis delivery. A necessary loading dose is a separate decision from the maintenance interval.

## Know the toxicity clues

Gabapentinoids or baclofen can cause sedation and myoclonus; cefepime can cause encephalopathy or seizures; accumulating anticoagulants can cause bleeding. New symptoms after a dose change should trigger a medication review before adding another drug to suppress them.

## Catch dangerous combinations

NSAID + diuretic + RAAS blockade can precipitate hemodynamic AKI. Trimethoprim plus RAAS/MRA therapy increases hyperkalemia risk. Azathioprine plus xanthine-oxidase inhibition can cause severe myelosuppression: febuxostat is contraindicated, not a safer substitute for allopurinol.

## Plan holds AND restarts

Specify the drug, illness trigger, contact route, and restart criteria. SGLT2 inhibitors are usually withheld during prolonged fasting, surgery, or critical illness. A temporary hold should not become permanent omission once intake, hemodynamics, and kidney function are reassessed.

## Close every transition

At admission, dialysis initiation, discharge, and recovery, reconcile indication, dose, timing, interactions, and OTC products. Document the next laboratory test and responsible clinician. Include dialysis-session timing for dialyzable drugs and residual kidney function when relevant.

## Supporting evidence

- [Supporting guideline or source](https://kdigo.org/wp-content/uploads/2026/04/KDIGO-2024-CKD-Guideline.pdf)
- [Supporting guideline or source](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=13a80059-46f7-4453-ab37-72744657a08a)

## Source lessons

- [renal pharmacology](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/renal-pharmacology.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.